Question 1

What is TARLATAMAB-DLLE used for?

Accepted Answer

TARLATAMAB-DLLE (brand name IMDELLTRA (AMG757)) is a Other indicated for See full prescribing information.

Question 2

How does TARLATAMAB-DLLE work?

Accepted Answer

TARLATAMAB-DLLE works through the following mechanism: 12.1 Mechanism of Action Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC..

Question 3

What are the most common side effects of TARLATAMAB-DLLE?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for TARLATAMAB-DLLE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is TARLATAMAB-DLLE the same as IMDELLTRA (AMG757)?

Accepted Answer

IMDELLTRA (AMG757) is a brand name for TARLATAMAB-DLLE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

TARLATAMAB-DLLE

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations